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1. ABSTRACT
Mitochondria are membrane-enclosed 
organelles, the energy-producing centers in almost 
all eukaryotic cells. The evolutionary emergence 
of mitochondria is a result of the endocytosis of 
a-proteobacteria. There are several characteristic 
features which refer to its prokaryotic ancestors 
including its independent sets of double-stranded 
mitochondrial DNA, which is uniquely circular in form 
and contains a significant amount of unmethylated DNA 
as CpG islands. Resent research has proven that free 
mitochondrial DNA found in blood was associated with 
innate immunomodulation in a broad-range of clinical 
conditions. Upon release, mitochondrial DNA acts as a 
danger-associated molecular pattern in the circulation, 
it is recognized by pattern recognition receptors and it 
facilitates inflammatory responses. Besides its high 
receptor activation potential, mitochondrial DNA is likely 
to perform direct crosstalk with activated leukocytes and 
to be contributed to other anti-microbial activities. Here 
we highlight the pathological conditions where cell free 
mtDNA is involved, describe the potential sources and 
mechanisms of extracellular mtDNA release and explore 
evidence for its mechanism of action after being excreted 
and potential therapeutic strategies.
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2. INTRODUCTION
Due to its high mutation rate, mitochondrial 
DNA (mtDNA) has been studied in the context of ageing-
related and multifactorial diseases where mitochondrial 
dysfunction is thought to play a role (1, 2). However, in 
the last few years, a novel and significant role of mtDNA 
has emerged, involving its ability to trigger innate immune 
system responses and drive inflammation when released 
from mechanically injured cells (3). MtDNA, along with 
other host molecules released upon cell damage, falls into 
the category of damage-associated molecular patterns 
(DAMPs). According to the endosymbiotic theory, the 
evolutionary emergence of mitochondria is a result of 
the endocytosis of a-proteobacteria (4, 5). Phylogenetic 
investigations support this assumption, as mitochondria 
possess several features characteristic of their prokaryotic 
ancestors, such as their barrel-shape and diameter of 0.2. 
to 1.0. µm. Mitochondria have their own independent sets 
of double-stranded mitochondrial DNA (mtDNA), which 
is not linear like nuclear DNA, but circular in form and 
consists of a high number of unmethylated CpG islands, 
as typically found in bacteria (6). The genome size of 
mtDNA is significantly smaller than the nuclear (16.5.69 bp 
vs. 3.2. billion bp) in humans, the number of encoding 
mitochondrial genes is only 37, which encode no more 
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than 16 proteins, all belonging to the electron transport-
chain (7). The release of mtDNA and its presence in the 
circulation were described to play a significant role in 
various clinical conditions; in particular, inflammatory 
diseases, several types of cancer and in conditions 
leading to critical illness requiring intensive care unit 
admission (8-10). Currently, several conditions are being 
explored where mechanical and chemical stress can 
lead to cellular necrosis accompanied by mtDNA release. 
This review will provide a summary of the pathological 
conditions where cell free mtDNA is involved, describe the 
potential sources and mechanisms of extracellular mtDNA 
release and explore evidence for its mechanism of action 
after being excreted and potential therapeutic strategies.
2.1. Conditions when mitochondrial DNA 
release is accompanied by mechanical and 
chemical stress
The release of mtDNA has been described in 
diverse inflammation and cell necrosis-related clinical 
conditions, where the loss of cell membrane integrity 
leads to the release of intracellular content (11). However, 
it is important to note that in these conditions, the stress 
destroying the mitochondria can be of either extracellular 
or intra-mitochondrial origin, with the latter case initiated 
by oxidative burst inside the mitochondrion, resulting in 
mitochondrial and cellular disintegration (12). As such, 
mechanisms of mtDNA release may vary depending on 
the origin and the type of insult.
2.1.1. Mechanical stress related mtDNA release
Any type of cell death that culminates in lysis 
and subsequent release of intracellular content into the 
extracellular environment could conceivably result in 
mtDNA being released into the circulation (11). MtDNA 
and other particles are not exposed to the innate 
immune system following normal apoptosis, but cell 
death due to mechanical stress and subsequent lysis 
can mediate their entry into the systemic circulation to 
provoke immune response (13). Tissue injury is one 
such example of mechanical stress leading to release 
of mtDNA (14). In major trauma patients, the initial 
cell death due to the injury is an important but non-
modifiable factor for post-injury inflammation-associated 
complications (15). The recognition of mtDNA by innate 
immune cells (primarily neutrophils) plays a pivotal role 
in the pathophysiology of sterile inflammation after major 
trauma (16). Our group has hypothesized that mtDNA 
may have a primary inflammatory source following 
major trauma rather than as a result of direct tissue 
injury and subsequent cell necrosis (17). It is supported 
by our recent findings, where elevated and increasing 
concentration of mtDNA was shown to be present in 
the sera of major trauma patients. We also identified 
sustained high concentrations of cell free mtDNA in the 
sera of postoperative trauma patients undergoing major 
orthopedic trauma surgery without association with well-
established markers of tissue necrosis (17).
2.1.2. Stress causes oxidative damage and a 
subsequent DNA release in mitochondria
In addition to its presence in major trauma 
patients, alterations in mtDNA content of the blood 
have been measured in a number of diseases relating 
to oxidative stress. Besides the measurable oxidative 
damage, the involvement of the mitochondrial genome 
was described in response to focal or acute myocardial 
ischemia/reperfusion in animal models and in human 
cells (18-20). Elevated blood mtDNA content was 
described to be in association with higher cardiovascular 
risk or development of coronary heart disease (21, 22). 
This latter study was conducted on patients with diabetes 
mellitus and others found hyperglycemia-induced 
elevation in mtDNA of the peripheral blood in early 
diabetes (23). Likewise, neurodegenerative diseases 
such as Alzheimer’s or Huntington’s disease are also 
seemed to be associated with alterations in mtDNA 
concentration (24-26). Also, different types of cancer 
or critical conditions like sepsis or hemorrhagic shock 
are considered to be connected with mtDNA copy 
number changes (16, 27-30). In the context of high-
altitude oxygen deprivation, blood mtDNA content was 
observed to be increased in lowlanders as compared to 
highlanders, regardless of age and gender, suggesting 
that the changes in mtDNA concentration might be due 
to the ROS-stress adaptation mechanisms (31, 32). Both 
acute and chronic inflammatory diseases have been 
associated with increased cell-free mtDNA and correlate 
with elevated free radical production that may have 
originated from mitochondria (33), but the question of 
the source of ROS remains open, as the ROS productive 
capacity of immune cells is also well-known in these 
conditions. Liu and co-workers published in 2003, that 
the copy number of mtDNA in human leukocytes was 
highly affected by alterations in plasma antioxidants/
pro-oxidants (34). In addition to its role in diseases itself, 
mtDNA is also affected by diagnostic and therapeutic tools. 
Mitochondria are highly susceptible to ionizing radiation 
at the clinically relevant dosages and oxidative stress 
resulting from irradiation was found to be accompanied by 
a rise in extracellular mtDNA release (35, 36). In fact, the 
natural process of aging is relevant here, since oxidative 
stress within aging mitochondria can lead to a vicious 
cycle in which damaged mitochondria produce increased 
amounts of reactive oxygen species. This could explain 
the significant increase in the mtDNA mutation rate also 
found in human clinical studies in healthy older people’s 
plasma, as compared to young volunteers (37, 38). 
The cut-off for clinically relevant rise in these mutations 
is likely to be close to the 6th decade of life in humans, 
highlighting the importance of age-matching in mtDNA 
concentration-based human studies (39).
Paradoxically, oxidative injury to mitochondria 
takes place during “reductive stress”: when electron 
acceptors are expected to be mostly reduced, some 
redox proteins can donate electrons to O2 instead, 
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which increases the NADH/NAD+ ratio of mitochondria. 
Conditions such as high-intensity exercise training, 
alcohol intake or chronic fatigue syndrome and other 
forms of hyperglycemia-induced diseases all result in 
reductive stress and were reported to be accompanied by 
cellular damage and therefore mtDNA excretion (40-42).
2.1.3. Cell death pathways culminating in lysis
If a cell is directly injured through a physical 
insult or severely stress it may become necrotic. Necrosis 
is characterized morphologically by cell rounding, 
swelling (oncosis), and expansion of organelles and 
de-condensation of nuclear chromatin (43). This process 
culminates in cell lysis. Recent evidence suggests that 
complex signal transduction mechanisms can control 
necrosis (43). Further cell death essentially occurs as 
a result of the physiological stress caused by the mass 
release of cytokines and other cell signaling molecules 
from injured tissues and the innate immune cells involved 
in the acute inflammatory response. “Necrosis” in the post-
injury state can be triggered through subsequent complex 
tightly regulated intracellular signaling cascades, not just 
through the initial mechanical tissue injury. Necrosis can 
be triggered by exogenous molecules such as TNFα 
and Fas ligand binding to cell surface receptors (44). 
The activation of such receptors can lead to a tightly 
regulated and controlled form of necrosis. This process 
is mediated through caspase-8 (anti-cell death enzyme) 
and receptor interacting protein kinases (RIPK family) 
and the term “necropoptosis” coined for it (11). The role 
of DAMPs in triggering necropoptosis has also been 
explored through their activation of pathogen recognition 
receptors (PRRs) which then trigger intracellular 
signaling cascades through RIPK1 and RIPK3 (11). 
Whilst RIPK1 and RIPK3 can play a role, they are not 
essential in necrosis following ischemia reperfusion (IR) 
injury (44). This is characterized by exposure to high 
levels of hydrogen peroxide (H2O2) and is dependent 
on the activity of a different enzyme poly (ADP-ribose) 
polymerase (44). Free intracellular iron redox reactions 
with H2O2 appear to play a pivotal role in this modality 
of cell death by inducing lysosomal permeability (43). 
Intracellular chelation of free iron was demonstrated to 
be cell-protective in such conditions (43). Regardless 
of the initiating stimulus, loss of membrane continuity 
and lysis leads to the extravasation of the intracellular 
contents, including mtDNA and associated mtDAMPs 
into the extra-cellular environment.
2.1.4. Oxidative cellular damage pathways 
initiated by mitochondria
The majority of ROS are products of 
mitochondrial respiration, as the electrontransport-chain 
contains several redox centers that may leak electrons 
to O2, serving as the primary source of O2
.− production 
in most tissues (12). A major threat to this controlled 
equilibrium is hypoxia, since the absence of the electron 
acceptor O2 leads to a shift in reducing potential to a 
higher than normal reducing power, which results in 
progressive structural and functional cell damage. It is 
therefore widely accepted that several disease states 
are linked to “oxidative stress” and a subsequent 
mtDNA release (45). The effect of abnormal Ca2+ is also 
inevitable in response to stress, but the mechanisms of 
the harmful effect of Ca2+ on mitochondria is not well 
characterized (46). ROS and Ca2+ constitute important 
mediators of the propagation of the necrotic signal from 
the mitochondrial matrix towards the outside and can 
cause damage to all of the major classes of biological 
macromolecules, including nucleic acids, proteins, 
carbohydrates, and lipids (47). Mitochondrial calcium has 
been described to stimulate oxidative phosphorylation, 
thereby promoting more ROS generation (48). In 
addition calcium-mediated activation of calpain can lead 
to cleavage and inactivation of caspases (49) whereas 
ROS can target the active site of caspases and render 
them inactive, promoting necrosis (50). Likewise, 
mitochondrial H2O2 can cause the release of cytochrome 
c from mitochondria into the cytosol and H2O2 may 
also activate nuclear transcription factors, like NF-κB, 
AP-1, and p53, which may upregulate death proteins or 
produce inhibitors of survival proteins (51).
3. CIRCULATING MITOCHONDRIAL DNA IN 
INNATE IMMUNE RESPONSES
Despite their seemingly independent existence 
within the cell, mitochondrial transcription and replication 
are co-dependent on nuclear encoded factors transported 
into mitochondria (52). The aforementioned similarity to 
bacterial DNA makes mtDNA highly immunostimulatory to 
cells of the innate immune system (6). The latest evidence 
suggests that it does not only facilitate antibacterial 
immune responses, but significantly contributes to 
further adverse effects and may have important roles 
in inflammatory diseases and complicated outcomes 
following cellular damage or oxido-reductive stress (8). 
MtDNA has been shown to bind PRRs, namely to the Toll-
like receptor (TLR) superfamily members or nucleotide 
oligomerization domain (NOD)-like receptors (NLRs) and 
more recently it has been shown to be linked with the 
stimulator of interferon genes (STING) pathway (53, 54).
3.1. MtDNA and TLR interaction
MtDNA has been demonstrated to induce 
neutrophil activation and facilitates adverse immune 
reactions through activation of TLR 4 (55) and 
TLR 9 (56), mediated through MAP kinases p38 (16, 57) 
and p44/42 (58). MtDNA triggers activation of the nuclear 
factor kappa B pathway (NFĸB) via TLR9, resulting in 
upregulation of pro-inflammatory cytokine production 
including TNF-α (59), IL-1β (60) and IL-6 (61). MtDAMPs 
have been shown to potentiate inflammatory lung injury 
when introduced into healthy rats in a landmark paper 
by Zhang and colleagues (9). One possible contributory 
factor is that mtDNA triggers increased neutrophil 
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expression of matrix metalloprotease 8 (MM8) through 
p38 activation, which is a collagen cleavage enzyme that 
potentiates tissue degradation (57).
3.2. MtDNA-Nod-like receptor 3 relationship
Of the NLR receptors NLR pyrin domain 3 
(NLRP3) inflammasome is the most widely studied 
mainly due to its affinity for a wide variety of ligands (62). 
Mitochondria have been implicated in the recruitment of 
NLRP3 in a variety of different ways including through 
direct activation with mtDNA (63). The assembly of 
the NLRP3 inflammasome in complexes containing 
caspase-1 has now been directly implicated in triggering 
a novel form of cell death termed “pyroptosis” (64). 
Interestingly when cells lack mtDNA (induced by 
treatment with ethidium bromide) NLRP3 inflammasome 
formation was completely inhibited (65). Conversely, 
NLRP3 inflammasome formation releases mtDNA (65). 
This indicates a possible positive feedback loop where 
mtDNA potentiates its own release by stimulating further 
NLRP3 inflammasome formation.
3.3. MtDNA-STING pathway relationship
MtDNA has the ability to stimulate the innate 
immune system through stimulation of interferon genes 
(STING) pathway, resulting in interferon release. The 
STING pathway was recently mechanistically dissected 
to reveal an intricate relationship demonstrating how 
mtDNA triggers interferon release (54). The study showed 
that through depletion of mitochondrial transcription 
factor A (TFAM) during a herpes viral infection, mtDNA 
stability was disturbed, causing enlargement of the 
mitochondrial nucleoid. Subsequently, fragmented 
mtDNA was released, activating peri-mitochondrial cyclic 
GMP-AMP synthase (cGAS) causing increased cGAMP 
formation. The second messenger cGAMP then activates 
the endoplasmic reticulum bound STING pathway which 
ultimately upregulates type I interferon (IFN I) expression 
which inhibits viral propagation. Interestingly, pro-
apoptotic caspase activation inhibits this response and 
suppresses downstream interferon production (66).
3.4. MtDNA-neutrophil extracellular trap 
formation
Neutrophil extracellular trap (NET) formation or 
“NETosis” was first described by Brinkmann and colleagues 
in 2004 (67). It is characterized by smooth extracellular 
filaments-17nm in diameter- which are composed of 
stacked and probably modified nucleosomes (68). This 
filamentous chromatin backbone is adorned with globular 
domains of approximately 50nm diameter containing 
neutrophilic granular proteins. The principle function of 
the NET is believed to be to entrap and kill circulating 
pathogens and this function has been directly shown in 
both Gram- and Gram+ bacteria, viruses and fungi (68, 69).
The composition of NETs was initially widely 
believed to be predominantly nuclear DNA (nDNA), 
however under specific stimulatory conditions NETs 
composed exclusively of mtDNA were demonstrated (70). 
Our group described that NETs formed after trauma and 
subsequent surgery were predominantly composed 
of mtDNA (71). More recently NETs rich in oxidized 
mtDNA have been discovered in systemic lupus 
erythematous (72). The emerging body of evidence 
suggesting NETs can indeed be composed exclusively or 
predominantly of mtDNA means NETosis may represent 
a significant source of circulating mtDNA in certain 
inflammatory conditions.
In addition to the role of intracellular mtDNA in 
NET composition, mtDNA may also trigger NET formation 
as a DAMP. NETosis has widely been considered as a 
NADPH oxidase (PHOX) dependent process, reliant on 
mitochondrial release of reactive oxygen species (73). 
However mtDNA as a trigger for NETosis is a much 
more recent concept and there is growing evidence that 
extracellular trap formation takes place independently 
from pro-oxidant activity (74, 75). MtDNA has been 
demonstrated to be a trigger for NETosis after major 
trauma and with signaling mediated through a TLR9-
dependent pathway, independent of PHOX (38). The 
concept of mtDNA as a signaling molecule involved in 
NETosis suggests it may have a more diverse role in 
regulating certain inflammatory processes in a novel and 
previously unstudied way.
4. CLINICAL IMPLICATIONS OF CELL-FREE 
mtDNA
4.1. Diagnostic application of mtDNA
The number of studies investigating the 
concentration of mtDNA as a potential biomarker in 
different human body fluids has grown significantly 
in recent years. Real-time PCR allows simultaneous 
detection and quantification of mtDNA using a small 
amount of sample and a downstream real-time PCR 
analysis give an accurate reproducible result within 
2 hrs. The detection from blood, saliva, urine or sperm 
is a minimally or non- invasive process for diagnosis and 
was proven to be valuable for the prognosis of various 
clinical conditions, such as different types of cancer, 
type 2 diabetes, sepsis, multiple organ failure, fertility 
impairment or neurodegenerative disorders (28, 76-81). 
However, the exact cellular mechanisms and cell-type of 
origin which cause mtDNA concentration to fluctuate in 
many conditions remain unclear.
Elevated mtDNA content in peripheral blood 
has been demonstrated as a diagnostic factor in various 
types of cancer, including non-Hodgkin lymphoma, lung 
cancer, pancreatic cancer, breast cancer, colorectal 
cancer, or glioma (81-86). In contrast, an increased 
risk of renal cancer or hepatocellular carcinoma was 
observed to be associated with decreased circulating 
mtDNA concentrations within the tumor tissues of 
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cancer patients (87, 88). In other human studies, 
mtDNA quantity measured in the blood of patients with 
sepsis, pulmonary embolism or out-of-hospital cardiac 
arrest was proven to be a more powerful prognostic 
marker than those conventionally used, including 
nuclear DNA or other existing semiquantitative score 
systems (89, 90).
The rapidly elevated concentrations of 
circulating mtDNA levels that are observed in trauma 
patients with severe injury suggests that extracellular 
DNA originates from direct tissue injury and subsequent 
necrosis. It was described to be a trustworthy prognostic 
marker either in blood or in cerebrospinal fluid with 
good prediction for unfavorable outcome, or even 
mortality (65, 91-93). Although, in some studies, nuclear 
DNA concentration and well-established markers of 
tissue necrosis were not found to correlate with mtDNA 
levels, or mtDNA concentration was observed to have 
no contribution in the pathophysiology of critical illness 
(17, 29, 94). These findings together with the above-
mentioned dichotomies, raise some concerns regarding 
the nucleic acid-based diagnosis. The reduced 
clearance of DNA over time caused by impaired 
organ function during systemic inflammation may also 
be a contributing factor (92) and similarly, the limited 
capacity of inflammatory cells for taking up dying cells, 
thereby DNA (95). In the near future, investigation of the 
mtDNA methylation pattern rather than its concentration 
might be used for the diagnostic purpose for identifying 
tissue specific origin, as it was successfully performed 
to predict cardiovascular problems or amyotrophic 
lateral sclerosis (96, 97) and suggests a promising 
approach to diagnose health problems caused 
by environmental pollution exposure, aging, drug 
treatment, and oxidative stress (98). Moreover, since 
mitochondria do not contain histones, it is likely that 
the mtDNA methylation/hydroxymethylation ratio rather 
than histone modification is important for mitochondrial 
genome-based diagnostics.
4.2. Therapeutical implications of mtDNA
Major trauma patients often require lifesaving 
allogenic blood products in which cellular remnants, 
such as mitochondria and extracellular mtDNA are 
described to be present and to mediate adverse 
inflammatory processes, as neutrophil, eosinophil 
and basophil leukocyte activation (99, 100). It is 
important to take into account, that platelet units 
represent a potential reservoir of mtDNA, since unlike 
leukodepleted red blood cell units, stored platelets 
contain mitochondria.
Moreover, other therapies might also cause 
cytolysis and may be accompanied by circulatory 
mtDNA release. Plasma mtDNA content was proven to 
be elevated and observed to mediate pro-inflammatory 
effects in maintained haemodialysis patients (101) and 
in another study, increased mtDNA amount in the plasma 
of patients was considered to be related to the overall 
procedure of artificial kidney therapy and probably was 
due to the death of leukocytes (102).
The fact that mtDNA has such potent 
immunostimulatory effects makes it an exciting target 
for immunomodulation therapy attenuating some 
of the potentially deleterious effects of excessive 
innate immune activation. Whether mtDNA is free or 
conjugated in NETs it is readily digestible with DNAse. 
There is certainly good evidence to suggest that focally 
targeting NETs with DNAse has yielded a reduction in 
associated inflammatory lung damage in a mouse model 
of transfusion related acute lung injury (TRALI) (103). 
Human recombinant DNAse therapy has been used to 
good effect when nebulized in cystic fibrosis patients 
by enhancing sputum solubilisation (104), however no 
studies have been performed in humans to treat acute 
inflammatory conditions. With such an emergent role of 
mtDNA in NETs associated with trauma (71) and more 
recently in SLE (105) the investigation of DNAse therapy 
in different inflammatory conditions would be very 
reasonable.
Targeting mtDNA receptors may also yield ways 
to modify its proinflammatory properties. It has a diverse 
role as a signalling molecule in various inflammatory 
pathways as a ligand of multiple receptors including 
mtDNA stimulation of the NLRP3 inflammasome (63), 
cGAS in mtDNA-STING pathway (54) and TLR9 in 
mtDNA mediated NETosis (38). Modulation of these 
receptors may convey benefit in a variety of clinical 
conditions and attenuate the immunostimulatory effects 
of mtDNA.
5. FUTURE DIRECTIONS
It is essential to understand the tissue specific 
origin of circulating mtDNA for both diagnostic and 
therapeutic considerations. The natural history of 
free polynucleotides in the circulation in inflammatory 
conditions is largely unknown. The available active 
DNAse concentration in physiological and pathological 
conditions could indicate the potential need for enzyme 
supplementation as a therapeutic strategy. We believe 
that our current knowledge on cell free circulating mtDNA 
is in a rather exploratory phase with a potential for the 
future to rewrite the pathology of the leading causes of 
morbidity and mortality such as inflammatory conditions, 
autoimmune disorders, cancer, heart disease, stroke and 
injury.
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